908 Devices Posts Record $19M Quarter, 35% Revenue Growth, Raises Guidance Floor
MASS has more than doubled off its 52-week low of $5.025.
Summary
908 Devices delivered Q3 2026 revenue of $19.0 million, up 35% year-over-year, with 308 devices placed in the quarter — a company record — and an installed base that grew 26% to 4,409 devices. The FTIR portfolio drove the product revenue jump to $15.8 million from $10.8 million a year ago, and the newly acquired NIRLab shipped roughly 100 units in its first full quarter. Recurring revenue of $5.1 million covered 27% of the top line, and adjusted gross margin held at 58%. The bottom line improved sharply: net loss from continuing operations narrowed to $4.6 million from $14.9 million, though most of that swing came from an $11.0 million noncash reduction in contingent consideration expense rather than operations — adjusted EBITDA loss was essentially flat at $1.7 million. Management raised the low end of full-year revenue guidance to $68.5 million-$70.0 million from $68.0 million-$70.0 million, implying 22%-25% growth, and the balance sheet carries $99.1 million in cash with no debt. This follows the Q2 print on August 11 that showed $16.1 million in revenue and a guidance raise; the acceleration to 35% growth is the key delta. The 8:30 am ET call today will be the venue for any detail on NIRLab pipeline and Q4 demand.
At the time of this announcement, MASS was trading at $11.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $475.8M. The 52-week trading range was $5.03 to $13.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.